

PRESS RELEASE

David Sourdivé, Vice President of Corporate Development at Collectis, has been appointed by French Foreign Trade Minister Nicole Bricq to boost France's export performance in the health sector

Paris, May 2nd 2013 - Collectis (Alternext: ALCLS), the French genome engineering specialist, has announced the appointment of David Sourdivé as head of the Treat Yourself Better initiative. This project aims to make France more competitive in the health sector. To this end, David Sourdivé will become France's "coordinator" on the international level, with the goal of assembling all market players so as to take advantage of new growth opportunities in the health sector.

In order to boost French foreign trade and respond to the emergence of new global needs, Nicole Bricq has established four priorities for action: Treat Yourself Better, Eat Better, Communicate Better and Live Better in the City, which target the sectors in which French industry has a competitive edge.

To direct these four projects, the Minister chose individuals who are particularly involved and recognized within their field.

The context of the Treat Yourself Better initiative, to be led by Collectis co-founder David Sourdivé, is that health expenses in emerging countries are increasing, in step with the aging population. This trend promises strong growth in the health market in the years to come.

Drawing upon France's innovation potential as well as a worldwide network of dedicated contacts, David Sourdivé's mission is to bring together health-sector stakeholders to help them establish a durable foothold on the global market.

Foreign Trade Minister Nicole Bricq said, "The government and all economic stakeholders are mobilizing to give French companies the resources they need in order to meet the expectations of an increasingly competitive global market and ensure lasting growth." In the words of David Sourdivé, "with a quality offering and a network of dynamic SMEs, particularly in the field of biotechnology, France is up to the challenge of growing global demand in the health sector. These entities do, however, need support if they are to effectively promote the French offering abroad."

A graduate of the *École Polytechnique*, David Sourdivé, PhD is Vice President of Corporate Development and co-founder of Collectis. After completing his doctorate in molecular virology at the *Institut Pasteur*, he joined one of the leading laboratories in viral immunology, at Emory University in Atlanta, Georgia (USA) to conduct research on immunological memory. Before founding Collectis, he was the director of the biotechnology laboratory at the *Centre d'études du Bouchet* for the French Ministry of Defense. He also has management training from the *HEC* (Challenge +).



About Collectis

Founded in France in 1999, the Collectis Group runs on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Co-initiated by André Choulika, its Chairman and Chief Executive Officer, Collectis is now one of the world's leading companies in the field of genome engineering, with revenue of €21 million in 2012. Collectis has a workforce of 230 employees working at 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States. The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. University College of London (UCL), the National Institute of Health (NIH), Novo Nordisk, The Center for iPS Cell Research and Application (CiRA), AFM, Novartis, BASF, Bayer, and Limagrain are some of the Group's clients and partners. Since 2007, Collectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris. For more information, visit our website: www.collectis.com.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Collectis

Philippe Valachs

Company Secretary

Tel: +33 (0)1 81 69 16 00

media@collectis.com